retatrutide weight loss trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Shows 28% Weight Loss

For anti-obesity GLP-1s, Medicares policy of not covering AOMs means that utilization skews heavily Commercial

Liraglutide (NN2211) is a long-acting GLP-1 receptor agonist used to treat type 2 diabetes and obesity (Victoza, Saxenda)

A new Ohio bill aims to restore state employees access to GLP-1 weight-loss medications after the state dropped coverage in early 2025, citing high costs ->

Imagine a single therapy that targets both appetite regulation and glucose control, tirzepatide is turning that vision into reality

Tiny portions

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act on the brain as well as the gut, and a 2026 real-world cohort study from Kamel-Abusalha et a